In antibody research, the use of mouse models is a key component in several discovery and production processes. For instance, when developing murine monoclonal antibodies, spleen cells of an antigen-exposed mouse are fused to human or mouse myeloma cells, which create the hybridomas needed to produce the desired single antibody clones.
The HAMA response occurs when the human immune system produces antibodies against mouse immunoglobulins or other mouse-derived proteins. When mice are used in research, human subjects (such as patients in clinical trials or individuals exposed to mouse-derived reagents) may develop HAMA due to their exposure to mouse antigens, interfering with therapeutic efficacy. This immune response can occur even after a single exposure and can persist for an extended period, with responses ranging from a mild rash to a life-threatening kidney failure.
To minimize the effect of HAMA on scientific research, researchers can employ several strategies:
Humanized Antibodies: Using humanized or fully human antibodies in research and clinical applications can mitigate the risk of HAMA response. These antibodies are designed to have minimal or no mouse-derived components, reducing the chances of immunogenicity in human subjects.
HAMA Testing and Monitoring: Determining baseline HAMA levels prior to initiation of therapy with murine-derived proteins can help to adjust dosages, interpret results accurately, and tailor treatment approaches accordingly.
Quality Control Measures: Implementing stringent quality control measures during the production and validation of mouse-derived proteins can help minimize potential HAMA-related issues.
Selection of Alternative Animal Models: Researchers can explore alternative animal models that are less likely to trigger the HAMA response. For instance, the use of in vitro techniques such as the production of recombinant monoclonal antibodies would prevent any issues.
At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
Antibodies are versatile molecules that perform a range of effector functions, many of which engage different arms of the immune system. Their modes of action extend beyond simple antigen binding, enabling the activation of various immune mechanisms that lead to pathogen neutralization and clearance. These functions include blocking molecular interactions, activating the complement system, and linking the humoral immune response to cellular immune responses via Fc receptor engagement.
In today’s competitive biotech landscape, intellectual property (IP) protection has become an essential pillar in fostering innovation and collaboration across drug discovery and development. By offering clear IP terms and no royalty fees,pharmaceutical companies and research institutes
In addition to isotypes and subtypes, antibodies exhibit genetic variation known as allotypes, which are polymorphic epitopes on immunoglobulins. These allotypic differences arise from allelic variations in immunoglobulin genes, causing certain antibody subtypes to differ between individuals or ethnic groups. The presence of these polymorphic forms can influence immune responses, particularly when an individual is exposed to a non-self allotype, potentially triggering an anti-allotype immune reaction.
In mammals, antibodies are classified into five major isotypes: IgA, IgD, IgE, IgG, and IgM. Each isotype is defined by the heavy chain it contains: alpha (IgA), delta (IgD), epsilon (IgE), gamma (IgG), or mu (IgM). These structural differences in the heavy chains determine the antibody's function, tissue localization, and role in the immune response. Furthermore, antibody light chains fall into two classes—kappa and lambda—with kappa being more common, though both exhibit similar functions despite differences in sequence.
